XIDX
RSGK
Market cap50mUSD
Jan 30, Last price
980.00IDR
Name
Kedoya Adyaraya Tbk PT
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PT Kedoya Adyaraya Tbk operates as an Indonesian healthcare enterprise, managing and owning hospitals throughout the country. The company delivers a broad spectrum of medical services across numerous specialties, encompassing comprehensive surgical procedures such as general, orthopedic, urological, cardiothoracic, plastic, and neurological operations. It also provides internal medicine subspecialties like nephrology, endocrinology, and general internal medicine, alongside care in obstetrics and gynecology, cardiology, neurology, pulmonology, ophthalmology, hyperbaric medicine, and pediatrics. Additional services include acupuncture, medical rehabilitation, and speech therapy. Oral health is addressed through oral and maxillofacial services, prosthodontics, and general dentistry. Furthermore, mental health support is provided by psychiatrists and psychologists, nutritional guidance by dietitians, and specialized treatment for skin and venereal conditions. Beyond these specialized areas, the company also offers general medical care. As of December 31, 2021, PT Kedoya Adyaraya Tbk operated two hospitals, offering a combined capacity of 200 patient beds. Established in 1990, the company's main office is located in Jakarta Barat, Indonesia, and it functions as a subsidiary of PT Sarana Meditama Metropolitan Tbk.
Valuation
Title IDR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||